论文部分内容阅读
80名初诊T2DM患者随机分为门冬胰岛素30治疗(甲)组、门冬胰岛素联合甘精胰岛素治疗(乙)组,治疗3个月后。结果:两组HbA1c、FA明显下降(P<0.05),F-CP体重明显增加(P<0.01);但甲组体重增加更明显。HbA1c、FA、F-CP、体重的差异无统计学意义(P>0.05)。甲组胰岛素日用量明显多于乙组(P<0.01)。两组HbA1c、F-CP变化的幅度差异无统计学意义(P>0.05),甲组患者体重增加的幅度明显高于乙组患者(P<0.01)。结论:早期胰岛素强化治疗使初诊T2DM患者HbA1c明显下降,胰岛β细胞功能明显改善,但门冬胰岛素30患者胰岛素日用量、体重增加幅度及低血糖发生率明显多于使用甘精胰岛素联合门冬胰岛素患者。
Eighty newly diagnosed T2DM patients were randomly assigned to treatment with insulin aspart 30 (arm A), insulin aspart and glargine (arm B) for 3 months. Results: The levels of HbA1c and FA decreased significantly in both groups (P <0.05), and the body weight of F-CP increased significantly (P <0.01). However, the weight gain of group A was more obvious. HbA1c, FA, F-CP, body weight difference was not statistically significant (P> 0.05). Group A insulin dose was significantly more than group B (P <0.01). There was no significant difference in the changes of HbA1c and F-CP between the two groups (P> 0.05). The weight gain of group A was significantly higher than that of group B (P <0.01). CONCLUSIONS: Early intensive insulin treatment significantly reduces HbA1c and pancreatic β-cell function in newly diagnosed T2DM patients. However, the insulin dosage, body weight gain, and incidence of hypoglycemia in insulin aspart 30 are significantly higher than those with insulin glargine and insulin aspart patient.